Back to Report Store Home

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

  • Published: Jul-2018
  • Report Code: GBIHC479MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Cancer Immunotherapies Drugs Market, Global, Frequency of Molecular Aberrations in Non-Small Cell Lung Cancer (%), 2018 34

Figure 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Breast Cancer, 2016–2023 38

Figure 3: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Leukemia, 2016–2023 39

Figure 4: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Lymphoma, 2016–2023 40

Figure 5: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Cutaneous Melanoma, 2016–2023 41

Figure 6: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for NSCLC, 2016–2023 42

Figure 7: Cancer Immunotherapies Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 50

Figure 8: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Revlimid ($bn), 2006–2024 52

Figure 9: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Opdivo ($bn), 2014–2024 55

Figure 10: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Keytruda ($bn), 2014–2024 57

Figure 11: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Tecentriq ($bn), 2016–2024 59

Figure 12: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Darzalex ($bn), 2015–2024 60

Figure 13: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Imfinzi ($bn), 2017–2024 62

Figure 14: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2006–2024 64

Figure 15: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Pomalyst ($bn), 2013–2024 66

Figure 16: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yescarta ($bn), 2018–2024 68

Figure 17: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gazyva ($bn), 2013–2024 69

Figure 18: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yervoy ($bn), 2011–2024 71

Figure 19: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006–2024 73

Figure 20: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Kymriah ($bn), 2017–2024 75

Figure 21: Cancer Immunotherapies Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 76

Figure 22: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Stage of Development, Molecule Type and Program Type, 2018 77

Figure 23: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 78

Figure 24: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018 79

Figure 25: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Molecular Target, 2018 81

Figure 26: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018 82

Figure 27: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006–2018 83

Figure 28: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2018 84

Figure 29: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2018 85

Figure 30: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2018 86

Figure 31: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018 87

Figure 32: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2018 88

Figure 33: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2018 89

Figure 34: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2018 90

Figure 35: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018 91

Figure 36: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2018 92

Figure 37: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2018 93

Figure 38: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2018 94

Figure 39: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018 95

Figure 40: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2018 96

Figure 41: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2018 97

Figure 42: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2018 98

Figure 43: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Lisocabtagene maraleucel ($m), 2018–2024 100

Figure 44: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Durvalumab plus Tremelimumab ($m), 2018–2024 101

Figure 45: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tremelimumab ($m), 2018–2024 103

Figure 46: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cemiplimab ($m), 2019–2024 104

Figure 47: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Epacadostat ($bn), 2020–2024 105

Figure 48: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Axalimogene filolisbac ($m), 2020–2024 107

Figure 49: Cancer Immunotherapies Drugs Market, Global, Market Size ($bn), 2017–2024 108

Figure 50: Cancer Immunotherapies Drugs Market, Global, Key Products Market Share, 2017–2024 112

Figure 51: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024 113

Figure 52: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune Checkpoint Proteins ($bn), 2017–2024 114

Figure 53: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2017–2024 116

Figure 54: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cytokine Signaling ($bn), 2017–2024 117

Figure 55: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for HPV Vaccines ($bn), 2017–2024 118

Figure 56: Cancer Immunotherapies Drugs Market, Global, Company Analysis Matrix, 2017–2024 119

Figure 57: Cancer Immunotherapies Drugs Market, Global, Cluster by Growth and Market Share, 2017–2024 120

Figure 58: Cancer Immunotherapies Drugs Market, Global, Forecast Market Share by Company (%), 2017–2024 122

Figure 59: Cancer Immunotherapies Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024 123

Figure 60: Cancer Immunotherapies Drugs Market, Global, Revenues by Route of Acquisition, 2017–2024 124

Figure 61: Cancer Immunotherapies Drugs Market, Global, Celgene Annual Revenue Forecast ($bn), 2017–2024 125

Figure 62: Cancer Immunotherapies Drugs Market, Global, Merck & Co Annual Revenue Forecast ($bn), 2017–2024 126

Figure 63: Cancer Immunotherapies Drugs Market, Global, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2017–2024 127

Figure 64: Cancer Immunotherapies Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2017–2024 128

Figure 65: Cancer Immunotherapies Drugs Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2017–2024 129

Figure 66: Cancer Immunotherapies Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2017–2024 130

Figure 67: Cancer Immunotherapies Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2017–2024 131

Figure 68: Cancer Immunotherapies Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2018–2024 132

Figure 69: Cancer Immunotherapies Drugs Market, Global, Gilead Sciences Annual Revenue Forecast ($bn), 2018–2024 133

Figure 70: Cancer Immunotherapies Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017–2024 134

Figure 71: Cancer Immunotherapies Drugs Market, Global, High-activity and Late-stage Pipeline Developers by Company Type, 2018 135

Figure 72: Cancer Immunotherapies Drugs Market, Global, Overall High-Activity and Late-Stage Pipeline Developers by Level of Cancer Immunotherapies Specialization, 2018 136

Figure 73: Cancer Immunotherapies Drugs Market, Global, Proportion of Total Company Revenue Attributed to Cancer Immunotherapies, 2017–2024 137

Figure 74: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Region, Deal Value and Year, 2006–2018 139

Figure 75: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Indication, 2006–2018 140

Figure 76: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018 141

Figure 77: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018 142

Figure 78: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018 155

Figure 79: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Indication, 2006–2018 156

Figure 80: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018 157

Figure 81: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018 158

Figure 82: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 1 178

Figure 83: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 2 179

Figure 84: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 3 180

Figure 85: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 4 181

Figure 86: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 5 182

Figure 87: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 6 183

Figure 88: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 7 184

Figure 89: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 8 185

Figure 90: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 9 186

Figure 91: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 10 187

Figure 92: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 11 188

Figure 93: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 12 189

Figure 94: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 13 190

Figure 95: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 14 191

Figure 96: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 15 192

Figure 97: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 16 193

Figure 98: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 17 194

Figure 99: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 18 195

Figure 100: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 19 196

Figure 101: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 20 197

Figure 102: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 21 198

Figure 103: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 22 199

Figure 104: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 23 200

Figure 105: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 24 201

Figure 106: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 25 202

Figure 107: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 26 203

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards